WO2018051895A1 - 乳酸菌を有効成分として含む、皮膚における特定細菌の異常増殖に起因する皮膚の状態の悪化を防止又は改善するための組成物 - Google Patents
乳酸菌を有効成分として含む、皮膚における特定細菌の異常増殖に起因する皮膚の状態の悪化を防止又は改善するための組成物 Download PDFInfo
- Publication number
- WO2018051895A1 WO2018051895A1 PCT/JP2017/032330 JP2017032330W WO2018051895A1 WO 2018051895 A1 WO2018051895 A1 WO 2018051895A1 JP 2017032330 W JP2017032330 W JP 2017032330W WO 2018051895 A1 WO2018051895 A1 WO 2018051895A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin
- bacteria
- lactic acid
- composition
- composition according
- Prior art date
Links
- 241000894006 Bacteria Species 0.000 title claims abstract description 107
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title claims abstract description 102
- 239000004310 lactic acid Substances 0.000 title claims abstract description 51
- 235000014655 lactic acid Nutrition 0.000 title claims abstract description 51
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 230000002159 abnormal effect Effects 0.000 title claims abstract description 37
- 230000006866 deterioration Effects 0.000 title claims abstract description 22
- 230000035755 proliferation Effects 0.000 title abstract 4
- 230000001580 bacterial effect Effects 0.000 claims abstract description 28
- 235000013305 food Nutrition 0.000 claims abstract description 24
- 241000191967 Staphylococcus aureus Species 0.000 claims description 38
- 235000014897 Streptococcus lactis Nutrition 0.000 claims description 34
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 14
- 230000037406 food intake Effects 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 11
- 206010000496 acne Diseases 0.000 claims description 11
- 241000194036 Lactococcus Species 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 8
- 201000004624 Dermatitis Diseases 0.000 claims description 7
- 241000186427 Cutibacterium acnes Species 0.000 claims description 6
- 206010016936 Folliculitis Diseases 0.000 claims description 6
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 6
- 229940055019 propionibacterium acne Drugs 0.000 claims description 6
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 5
- 206010007882 Cellulitis Diseases 0.000 claims description 3
- 201000000297 Erysipelas Diseases 0.000 claims description 3
- 206010021531 Impetigo Diseases 0.000 claims description 3
- 208000006311 Pyoderma Diseases 0.000 claims description 3
- 206010040954 Skin wrinkling Diseases 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 230000037303 wrinkles Effects 0.000 claims description 3
- 208000012868 Overgrowth Diseases 0.000 claims description 2
- 241000194035 Lactococcus lactis Species 0.000 claims 2
- 206010011224 Cough Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 36
- 208000017520 skin disease Diseases 0.000 abstract description 18
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 230000001717 pathogenic effect Effects 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 82
- 244000057717 Streptococcus lactis Species 0.000 description 32
- 230000000844 anti-bacterial effect Effects 0.000 description 24
- 238000012360 testing method Methods 0.000 description 19
- 244000052616 bacterial pathogen Species 0.000 description 18
- 206010040882 skin lesion Diseases 0.000 description 17
- 231100000444 skin lesion Toxicity 0.000 description 17
- 239000002609 medium Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 238000000034 method Methods 0.000 description 14
- 235000000891 standard diet Nutrition 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 12
- 230000003902 lesion Effects 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 239000000047 product Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 206010040872 skin infection Diseases 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 244000000010 microbial pathogen Species 0.000 description 7
- 208000035143 Bacterial infection Diseases 0.000 description 6
- 241000186660 Lactobacillus Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- 208000022362 bacterial infectious disease Diseases 0.000 description 6
- 230000003628 erosive effect Effects 0.000 description 6
- 239000002054 inoculum Substances 0.000 description 6
- 229940039696 lactobacillus Drugs 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 210000002615 epidermis Anatomy 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 101710125314 Beta-defensin 1 Proteins 0.000 description 4
- 101710125296 Beta-defensin 3 Proteins 0.000 description 4
- 206010033733 Papule Diseases 0.000 description 4
- 206010039509 Scab Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 3
- 101710177037 Beta-defensin 14 Proteins 0.000 description 3
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- 239000007993 MOPS buffer Substances 0.000 description 3
- 206010037888 Rash pustular Diseases 0.000 description 3
- 206010066409 Staphylococcal skin infection Diseases 0.000 description 3
- 241000191940 Staphylococcus Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000005713 exacerbation Effects 0.000 description 3
- 235000019985 fermented beverage Nutrition 0.000 description 3
- 235000021107 fermented food Nutrition 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 229960004184 ketamine hydrochloride Drugs 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 208000029561 pustule Diseases 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000008719 thickening Effects 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 102100037437 Beta-defensin 1 Human genes 0.000 description 2
- 102100026887 Beta-defensin 103 Human genes 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000186429 Propionibacterium Species 0.000 description 2
- 101150060340 S100a8 gene Proteins 0.000 description 2
- 206010041929 Staphylococcal scalded skin syndrome Diseases 0.000 description 2
- 241000750300 Staphylococcus aureus MW2 Species 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 239000002390 adhesive tape Substances 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 244000005714 skin microbiome Species 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 101150082072 14 gene Proteins 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102100039803 Beta-defensin 114 Human genes 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 208000021326 Ritter disease Diseases 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000012265 beta-defensin Human genes 0.000 description 1
- 108050002883 beta-defensin Proteins 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 235000012180 bread and bread product Nutrition 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000014048 cultured milk product Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 235000019520 non-alcoholic beverage Nutrition 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920001289 polyvinyl ether Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000008491 skin homeostasis Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/21—Streptococcus, lactococcus
- A23V2400/231—Lactis
Definitions
- the present invention is a composition comprising a lactic acid bacterium having an effect of treating or preventing an abnormal growth of bacteria that infects the skin and deteriorates the skin condition when taken orally or a skin disease caused by the infection.
- Non-Patent Document 1 In recent years, in relation to specific skin diseases (such as atopic dermatitis), an association between abnormal growth of Staphylococcus aureus and exacerbation of clinical symptoms has been suggested (see Non-Patent Document 1). It has been suggested that there is a great link between the risk of bacterial infection and abnormal growth and skin disease even in skin diseases that were not known to be involved.
- the treatment of infections in the skin has a very important role because bacterial infections and viral infections have different methods.
- treatment is mainly carried out by administration of antibiotics, but there is a risk of appearance of resistant bacteria due to heavy use of antibiotics.
- viral infections some antiviral drugs remain in symptomatic therapy because they are present only in infections of some viral species.
- Lactobacillus delbruecki (see Patent Document 3) and Lactobacillus boukenrai (see Patent Document 4), which are lactic acid bacteria that suppress infection by binding to transient pathogenic skin bacteria and inhibiting growth, are known. ing.
- Lactobacillus sanibili Lactobacillus salvarius
- Lactobacillus pentosas adheres to Staphylococcus aureus, Pseudomonas aeruginosa, and Streptococcus pyogenes and causes growth inhibition (see Patent Document 5). ).
- the present invention provides a food composition and a pharmaceutical composition for preventing or improving deterioration of the skin condition caused by abnormal growth of specific bacteria by orally ingesting a composition containing lactic acid bacteria. Objective.
- the present inventors have intensively studied whether or not the ingestion of lactic acid bacteria can reduce the deterioration of the skin condition that occurs when specific bacteria grow abnormally.
- the present invention is as follows.
- [1] A composition containing lactic acid bacteria as an active ingredient for suppressing abnormal growth of bacteria by oral ingestion or preventing or improving deterioration of skin conditions caused by abnormal growth of bacteria.
- Bacteria are Staphylococcus aureus, Staphylococcus epidermidis, group A ⁇ -hemolytic streptococci (Streptococcus pyogenes), Pseudomonas aeruginosa, fluorescent chromophoric diphtheroid (Fluorescent diphtheroid) and the composition of [1] selected from the group consisting of Propionibacterium acnes.
- composition according to [2], wherein the bacterium is selected from the group consisting of Staphylococcus aureus, Staphylococcus epidermidis, and Propionibacterium acnes.
- composition according to [9] The composition according to [7] or [8], wherein the skin condition resulting from abnormal bacterial growth is rough skin and dermatitis.
- composition according to [8] which is selected from the group consisting of salt, chronic pyoderma and acne vulgaris.
- a food composition and a pharmaceutical composition having an effect of suppressing abnormal growth of specific bacteria in the skin and preventing or improving deterioration of the skin condition can be provided.
- the present invention is a composition for preventing or improving deterioration of the skin condition caused by abnormal growth of specific bacteria, which contains lactic acid bacteria as an active ingredient.
- ⁇ Deterioration of skin condition caused by abnormal growth of bacteria includes rough skin, swelling, eczema, etc., and further includes skin condition deteriorated by infection with pathogenic bacteria.
- the composition of the present invention may reduce or suppress the severity of skin lesions resulting from skin infection with pathogenic bacteria.
- Skin lesions include papules and erosions in the skin, scabs, epidermis thickening, pustules, erosion / ulcers, intercellular edema, intracellular edema in the epidermis, and inflammatory cell infiltration in the dermis and subcutaneous tissue.
- the compositions of the present invention reduce these degrees.
- the skin condition resulting from the abnormal growth of bacteria includes skin diseases caused by infection with pathogenic bacteria. Skin diseases caused by infection with pathogenic bacteria are also called skin infections caused by pathogenic bacteria.
- the skin disease is preferably rough skin or dermatitis with inflammation.
- the present invention contains a lactic acid bacterium as an active ingredient, a composition for suppressing or preventing the deterioration of skin conditions caused by abnormal growth of specific bacteria, and a composition for treating or preventing skin infections caused by pathogenic bacteria It is also a thing.
- Bacteria that cause abnormal growth or deterioration of skin condition during infection include bacteria belonging to the genus Staphylococcus such as Staphylococcus aureus and Staphylococcus epidermidis; group A ⁇ -hemolytic streptococci (S. pyogenes) Bacteria belonging to streptococci such as Streptococcus pyogenes; bacteria belonging to the genus Pseudomonas such as Pseudomonas aeruginosa; bacteria belonging to the genus Corynebacterium such as fluorescent chromogenic diphtheroids; Propionibacterium bacteria belonging to the genus Propionibacterium such as acnes).
- Staphylococcus such as Staphylococcus aureus and Staphylococcus epidermidis
- group A ⁇ -hemolytic streptococci S. pyogenes
- Bacteria belonging to streptococci such as Streptococc
- composition of the present invention can be used for the suppression, treatment or prevention of deterioration of the skin condition caused by abnormal growth or infection of these bacteria, and particularly preferably the suppression of deterioration of the skin condition caused by Staphylococcus aureus.
- Examples of skin diseases that can be treated or prevented by the composition of the present invention include the following diseases.
- the skin disease names and causative bacteria are shown below. However, the following skin diseases are examples, and are not limited to these.
- ⁇ Tobihi infectious impetigo
- Staphylococcus aureus Staphylococcus epidermidis and Neisseria acne ⁇ Setsu (can) and acupuncture (yo) Settlement and wrinkles are those in which folliculitis has progressed.
- Staphylococcus aureus and Staphylococcus epidermidis Bacterial nail circumference Staphylococcus aureus, group A ⁇ -hemolytic streptococci and Pseudomonas aeruginosa ⁇ Multiple sweat gland abscess (staphylococcal peritonitis) Staphylococcus aureus ⁇ Chronic pyoderma Staphylococcus aureus and Staphylococcus epidermidis ⁇ Acne vulgaris (losing razor) Staphylococcus aureus and Staphylococcus epidermidis ⁇ Red tinea Fluorescent diphtheroid
- atopic dermatitis has also been reported to be exacerbated by infection with Staphylococcus aureus, and the composition of the present invention is a symptom of atopic dermatitis. It can also be used for mitigation and improvement.
- Lactococcus lactisCM JCM5805 can be obtained from RIKEN BioResource Center (1-3 Takanodai, Tsukuba City, Ibaraki Prefecture, Japan).
- a strain equivalent to Lactococcus lactis JCM5805 can be used.
- the equivalent strain refers to a strain derived from the above strain, a strain from which the above strain is derived, or a progeny strain of the strain.
- Equivalent strains may be stored in other strain storage institutions.
- Other strain preservation institutions include, for example, American type culture collection (USA), Tokyo University of Agriculture, strain preservation room (Japan, 1-1 1-1 Sakuragaoka, Setagaya-ku, Tokyo). It is not limited.
- the composition of the present invention contains a culture of the above lactic acid bacteria.
- a culture is a live cell, dead cell, live cell or crushed product of dead cell, lyophilized product of live cell or dead cell, crushed product of the lyophilized product, culture solution, culture solution extraction Such as lactic acid bacteria and treated products of lactic acid bacteria.
- the DNA or RNA of the lactic acid bacteria is also included in the culture of lactic acid bacteria.
- Lactic acid bacteria can be cultured by a known method using a known medium.
- a known medium commercially available medium for lactic acid bacteria culture such as MRS medium, GAM medium, LM17 medium, etc. can be used, and inorganic salts, vitamins, amino acids, antibiotics, serum, etc. may be added as appropriate.
- the culture may be performed at 25 to 40 ° C. for several hours to several days.
- the lactic acid bacteria are collected by centrifugation or filtration.
- dead bacteria it may be used after being sterilized by an autoclave or the like.
- antibacterial genes antibacterial genes
- Proteins that are the expression products of antibacterial genes bind to bacteria, destroy the bacterial cell membrane, and kill the bacteria.
- antibacterial genes include ⁇ -defensin 1 (BD-1), ⁇ -defensin 3 (BD-3), ⁇ -defensin 14 (BD-14), S100A8, and the like.
- a lactic acid bacterium having an effect of treating or preventing skin infections on a living body is preferable even when taken orally.
- a lactic acid bacterium is highly resistant to gastric juice and intestinal fluid.
- the lactic acid bacterium has strong acid resistance and can reach the intestinal tract while remaining alive.
- the aforementioned Lactococcus lactis JCM5805 can exert a therapeutic or preventive effect on skin infections even when taken orally.
- the composition of the present invention includes a food composition, that is, a food or drink.
- the food composition can be used for preventing or improving the deterioration of the skin condition caused by abnormal growth of the above-mentioned specific bacteria such as rough skin, swelling, eczema and infection of pathogenic microorganisms.
- Preventing or improving the deterioration of skin condition caused by abnormal growth of specific bacteria or infection of pathogenic microorganisms means suppressing abnormal growth of specific bacteria or infection of pathogenic microorganisms, and worsening skin inflammation. It means to suppress.
- Lactic acid bacteria themselves can be used as a food composition, but lactic acid bacteria can also be used in foods and drinks.
- the types of foods and drinks to be targeted are not particularly limited as long as the active ingredients for alleviating and improving symptoms of skin diseases caused by abnormal growth of specific microorganisms or infection with pathogenic bacteria are not inhibited.
- milk and dairy products beverages; seasonings; alcoholic beverages; processed agricultural and forestry foods; confectionery and bread products; flour and noodles; processed marine products; processed livestock products; processed fats and oils; processed frozen products; Instant foods; food materials.
- fermented milk products such as yogurt and cheese
- lactic acid bacteria beverages, or beverages such as soft drinks, non-alcoholic beverages, and sports beverages can be used.
- the lactic acid bacteria can be added to the fermented food or drink as dead bacteria, and the fermented food or drink can be produced using a lactic acid bacteria starter.
- food compositions include dietary supplements, food additives (food additives), and the like.
- the foods and drinks of the present invention include functional display foods, health foods and drinks, specific health foods and drinks, nutritional functional foods and drinks, health supplement foods and drinks, and the like.
- the food and drink for specified health use refers to food and drink that is ingested for the purpose of specific health in the eating habits and displays that the purpose of the health can be expected by the intake.
- functional labeling food means food that is reported to the Consumer Affairs Agency on the responsibility of the business operator to indicate functionality on the product package based on scientific grounds.
- a food composition containing lactic acid bacteria may be taken orally to alleviate and improve the abnormal growth of certain microorganisms or the condition of the skin infected with pathogenic bacteria. Can be prevented from growing abnormally and pathogenic bacteria from infecting the skin. Moreover, even when pathogenic microorganisms are infected, it is possible to suppress the growth of pathogenic bacteria. That is, the symptoms of skin diseases caused by abnormal growth of specific microorganisms or infection with pathogenic bacteria can be alleviated and improved, and the exacerbation of skin lesions can be suppressed.
- the composition for treating or preventing a skin disease caused by infection with a pathogenic bacterium comprising the lactic acid bacterium of the present invention as an active ingredient includes a pharmaceutical composition.
- the pharmaceutical composition can be used for the treatment or prevention of skin diseases caused by infection with the above pathogenic bacteria.
- the pharmaceutical composition can be used for alleviating and ameliorating the symptoms of skin diseases caused by infection with the above pathogenic bacteria, and suppressing the exacerbation of skin lesions caused by infection with the above pathogenic bacteria.
- the pharmaceutical composition comprises a therapeutic or preventive agent for skin diseases caused by infection with pathogenic bacteria, an agent for alleviating and ameliorating symptoms of skin diseases caused by infection with pathogenic bacteria, and skin lesions resulting from infection with pathogenic bacteria. It can also be said that it is an inhibitor of hate.
- the form of the pharmaceutical composition is not particularly limited. For example, powder, granule, tablet, syrup and the like can be mentioned.
- the pharmaceutical composition of the present invention is preferably administered orally.
- the pharmaceutical composition may contain an excipient, a disintegrant, a binder, a lubricant, a colorant and the like.
- Excipients include glucose, lactose, corn starch, sorbit, etc.
- Disintegrants include starch, sodium alginate, gelatin powder, calcium carbonate, calcium citrate, dextrin, and binders include dimethylcellulose, polyvinyl alcohol, and polyvinyl ether.
- the dose can be appropriately determined according to the age, weight, sex, disease difference, and symptom level of the patient to be administered, and it may be administered once or divided into several times a day to make the number of bacteria once.
- An amount of culture corresponding to 1 ⁇ 10 9 to 1 ⁇ 10 12 cells may be administered.
- 1 to 1000 mg, preferably 20 to 300 mg, may be administered once in terms of dry weight of lactic acid bacteria.
- the present invention includes a lactic acid bacterium for suppressing abnormal growth of bacteria by oral ingestion or preventing or improving deterioration of the skin condition caused by abnormal growth of bacteria.
- the present invention also includes a method for suppressing abnormal bacterial growth, including administering lactic acid bacteria, or a method for preventing or improving the deterioration of skin conditions caused by abnormal bacterial growth.
- the present invention includes the use of lactic acid bacteria for producing a pharmaceutical composition for preventing or improving the deterioration of the skin condition caused by the abnormal growth of bacteria or the method of suppressing the abnormal growth of bacteria.
- Staphylococcus aureus solution The Staphylococcus aureus used in the present invention was prepared by the following method. ⁇ Experiment method> Staphylococcus aureus MX2 was obtained from the American Type Culture Collection (ATCC), a US biological resource bank. After each test, add 10 mL of normal bouillon medium (Eiken Co., Ltd.) to the test tube, thaw the frozen bacterial solution, inoculate 100 ⁇ L, and then incubate at 37 ° C in a constant-temperature shaking incubator (Tytec Corp.). did.
- ATCC American Type Culture Collection
- the cultured bacterial suspension was centrifuged with a centrifuge (1000 rpm, 5 minutes), and the supernatant was removed.
- 2 mL of physiological saline was added and stirred to obtain an inoculum stock solution.
- the inoculum stock solution was diluted with a physiological saline solution and visually adjusted to a turbidity of 1 using the McFarland turbidimetric method.
- a part of the bacterial solution prepared in McFarland 1 was collected and diluted 100 times with physiological saline to obtain an inoculated bacterial solution.
- a part of the inoculum is collected, diluted 10 3 , 10 4 times with physiological saline, smeared on a normal agar medium, and then a 37 ° C incubator (MTR- 251 and Sanyo Electric Co., Ltd.) for 2 days. After culturing, the number of colonies was counted with a pen-type colony counter, the number of viable bacteria contained in 1 mL of the inoculum was calculated, and the bacterial concentration (cfu / mL) was confirmed.
- the S. aureus concentration used in Example 2 was 3.4 ⁇ 10 6 cfu / mL
- the S. aureus concentration used in Example 3 was 3.0 ⁇ 10 6 cfu / mL.
- Example 2 Analysis of protective action of Lactococcus lactis JCM5805 against staphylococcus aureus skin infection Sactococcus staphylococcus was inoculated into the skin of mice ingested orally with Lactococcus lactis JCM5805 to evaluate the degree of lesion, and to determine the viable count of Staphylococcus aureus Histopathological examination and antibacterial gene expression were performed to evaluate the protective effect against bacterial infection.
- the lesion score may be a skin lesion degree or a skin lesion score.
- BALB / C mice purchased from Japan SLC Co., Ltd., 5-week-old female
- standard diet intake group AIN-93G diet / Oriental Yeast Co., Ltd.
- Lactococcus lactis JCM5805 mixed administration group Lactococcus 2 groups of lactis JCM5805 intake group
- the dosage of lactic acid bacteria was set to 1 mg per animal per day.
- the start of administration of lactic acid bacteria is day 0, and ketamine hydrochloride anesthesia (intramuscular administration, 2.0 mL / kg, ketamine hydrochloride injection solution; Veterinary ketalal (registered trademark) 50 injection solution; Bayer Yakuhin Co., Ltd.) on day 14
- ketamine hydrochloride anesthesia intramuscular administration, 2.0 mL / kg, ketamine hydrochloride injection solution; Veterinary ketalal (registered trademark) 50 injection solution; Bayer Yakuhin Co., Ltd.
- a hair removal cream epilat (registered trademark), Kracie Home Products Co., Ltd.
- test site On day 15 of administration, under ketamine hydrochloride anesthesia, the test site was again stripped 3 times with a cloth adhesive tape, and then 0.1 mL (3.4 ⁇ 10 6) of the inoculum of S. aureus was injected into the test site using a micropipette. 5 cfu / head) was added dropwise.
- test site samples 8 mice in each group were used for viable count in the skin, and the remaining 8 mice were used for histopathological examination specimens.
- ear sample samples of all individuals were used for antibacterial gene expression analysis by quantitative PCR.
- a skin sample at a test site was cut into pieces, and then homogenized in 2 mL of physiological saline using a stirrer to obtain a skin tissue fluid. A part of the skin tissue fluid was collected, and a skin tissue diluted solution diluted with physiological saline to an optimum concentration was prepared. 100 ⁇ L of skin tissue dilution is smeared onto Staphylococcus agar (Eiken Co., Ltd.) using a large stick and cultured at 37 ° C for 2 days. The number of colonies contained in the entire test site (cfu / head) was calculated.
- a skin sample of the test site was embedded in paraffin according to a conventional method, a HE (Hematoxylin-Eosin) -stained tissue specimen was prepared, and the histopathological examination was performed.
- examination items scab, epidermis thickening, pustules, erosion / ulcer, intercellular edema, and intracellular edema were examined in the epidermis.
- the degree of inflammatory cell infiltration in the dermis and subcutaneous tissue was examined. The degree of each test item was evaluated on a scale of 0: asymptomatic, 1: mild, 2: moderate, 3: severe.
- cDNA was synthesized from 200 ng of total ng RNA ng, using this as a template, S100A8 gene, ⁇ -defensin 1 gene, ⁇ -defensin 3 gene, ⁇ -defensin 14 gene ( Real-time PCR analysis was performed on the expression level of GAPDH gene as a reference.
- SYBR Premix Ex Taq (TaKaRa) was used, and the primer sequences shown in Table 1 were used.
- the thermal cycler used was a LightCycler® 480II from Roche. After holding at 95 ° C. for 10 seconds, 50 cycles of reaction at 95 ° C. for 10 seconds, 50 ° C. for 5 seconds, and 72 ° C. for 10 seconds were performed.
- the Mann-Whitney U test was used, and for the antibacterial gene expression in the ear, using the Student t test, the Lactococcus lactis JCM5805 intake group and the standard diet intake group were significant. A difference test was performed. ⁇ Result> As shown in FIG. 1, the Lactococcus lactis JCM5805 intake group was found to have a significantly lower skin lesion degree due to S. aureus skin infection than the standard diet intake group. In other words, Lactococcus lactis JCM5805 was shown to have a reducing effect on the severity of skin lesions caused by S. aureus skin infection.
- Lactococcus lactis JCM5805 ingestion group compared to the standard diet intake group, including scab, epidermis thickening, pustules, intercellular edema, and intracellular edema, including inflammatory cell infiltration in the dermis and subcutaneous skin.
- the average score was low. That is, it was shown that Lactococcus lactis JCM5805 has an action of suppressing the severity of skin lesions caused by S. aureus skin infection.
- the Lactococcus lactis JCM5805 intake group compared to the standard diet intake group, the ⁇ -defensin 3 gene, ⁇ -defensin, which is an antibacterial gene in the ear that is not infected with Staphylococcus aureus 14 gene expression was significantly higher.
- the tendency of high expression of S100A8 gene and ⁇ -defensin 1 gene was recognized. That is, Lactococcus oclactis JCM5805 was shown to have an action of enhancing the expression of antibacterial genes in the skin.
- Lactococcus lactis JCM5805 enhances the expression of antibacterial genes in the skin and suppresses bacterial growth during Staphylococcus aureus skin infection. It was inferred that the various skin lesions that occurred as a result were severely suppressed.
- Lactococcus lactis JCM5805 suppresses the severity of skin lesions caused by Staphylococcus aureus Skin of mice caused by oral ingestion of Lactococcus lactis JCM5805 shown in Example 2 is inoculated with Staphylococcus aureus By measuring the degree of lesions over time, the protective effect against bacterial infection was evaluated for the period until the lesions were in remission.
- mice purchased from Japan SLC Co., Ltd., 5-week-old female
- 1 group of standard diet intake group AIN-93G diet
- Lactococcus lactis JCM5805 mixed administration group Lactococcus lactis JCM5805 intake group
- Two groups were set up.
- the dose of lactic acid bacteria, administration method, and inoculation with Staphylococcus aureus were performed in the same manner as in Example 2, and the degree of skin lesions was evaluated from day 0 to day 6 after inoculation with Staphylococcus aureus.
- the skin lesion score may be a lesion score value or a lesion score.
- FIG. 4 shows the skin lesion score after S. aureus infection.
- the Lactococcus lactis JCM5805 intake group was found to have a low lesion score at all time points compared to the control group.
- Lactococcus lactis JCM5805 has an action of suppressing the severity of skin lesions induced by Staphylococcus aureus skin infection.
- Example 4 Antibacterial activity against staphylococcus aureus in the skin when Lactococcus lactis JCM5805 was ingested The antibacterial activity against Staphylococcus aureus was compared with that of a standard diet using an extract of the skin of a mouse that had been orally ingested with Lactococcus lactis JCM5805.
- the antibacterial properties of the skin extract against Staphylococcus aureus were evaluated.
- the Staphylococcus aureus MW2 strain cultured in a normal broth medium was collected at 1 ⁇ 10 7 CFU, and the suspension was replaced with 5 mM MOPS buffer (pH 6.8) (manufactured by Dojindo).
- the mouse skin extract was added to the bacterial solution so as to be 5 ⁇ g / mL, and cultured at 37 ° C. for 4 hours. After culturing for 4 hours, the bacterial solution was diluted moderately (100-fold or 1000-fold with a medium) and seeded on a normal bouillon agar medium using a spiral plater (manufactured by IUL Instrument). After culturing at 37 ° C. for 24 hours, the number of colonies was counted using an automatic colony counter aCOLyte (manufactured by Symbiosis) to determine the number of bacteria.
- the antibacterial properties of the skin extract against Staphylococcus epidermidis were evaluated.
- a Staphylococcus epidermidis JCM12993 strain cultured in a normal broth medium was collected in an amount equivalent to 1 ⁇ 10 7 CFU, and the suspension was replaced with 5 mM MOPS buffer (pH 6.8).
- the mouse skin extract was added to the bacterial solution so as to be 5 ⁇ g / mL, and cultured at 37 ° C. for 4 hours. After culturing for 4 hours, the bacterial solution was diluted moderately (100-fold or 1000-fold with a medium) and seeded on a normal bouillon agar medium using a spiral plater. After culturing at 37 ° C. for 24 hours, the number of colonies was counted using aCOLyte, and the number of bacteria was measured.
- the antibacterial properties of the skin extract against acne bacteria were evaluated.
- Propionibacterium acnes JCM6425 strain cultured in brain heart infusion medium (Eiken Co., Ltd.) was collected in an amount equivalent to 1 ⁇ 10 6 CFU, and the suspension was replaced with 5 mM MOPS buffer (pH 6.8).
- the mouse skin extract was added to the bacterial solution so as to be 5 ⁇ g / mL, and cultured at 37 ° C. for 4 hours. After culturing for 4 hours, the bacterial solution was diluted moderately (100-fold or 1000-fold with a medium) and seeded on a brain heart infusion agar medium using a spiral plater. After culturing at 37 ° C. for 24 hours, the number of colonies was counted using aCOLyte, and the number of bacteria was measured.
- the number of bacteria in the Lactococcus lactis JCM5805 intake group is significantly smaller than that in the standard diet intake group compared to the Staphylococcus epidermidis JCM12993 strain, indicating that the antibacterial activity is increased. It was.
- the Lactococcus lactis JCM5805 intake group has a significantly reduced number of bacteria and increased antibacterial activity compared to the Propionibacterium acnes JCM6425 strain compared to the standard diet intake group. It was.
- the lactic acid bacteria capable of preventing or improving the deterioration of the skin condition resulting from the infection of the specific bacteria of the present invention can be used as an active ingredient in medicines, functional foods and foods and drinks for specific health use.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Physiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
[1] 乳酸菌を有効成分として含む、経口摂取により、細菌の異常増殖を抑制し、又は細菌の異常増殖に起因する皮膚状態の悪化を防止又は改善するための組成物。
[2] 細菌が黄色ブドウ球菌(Staphylococcus aureus)、表皮ブドウ球菌(Staphylococcus epidermidis)、A群β溶血性連鎖球菌(化膿レンサ球菌)(Streptococcus pyogenes)、緑膿菌(Pseudomonas aeruginosa)、蛍光発色性ジフテロイド(蛍光ジフテロイド)及びアクネ桿菌(Propionibacterium acnes)からなる群から選択される[1]の組成物。
[3] 細菌が黄色ブドウ球菌(Staphylococcus aureus)、表皮ブドウ球菌(Staphylococcus epidermidis)、アクネ桿菌(Propionibacterium acnes)からなる群から選択される、[2]の組成物。
[4] 前記乳酸菌が、ラクトコッカス属に属するものである、[1]~[3]のいずれかの組成物。
[5] 前記乳酸菌が、ラクトコッカス・ラクティスである、[1]~[3]のいずれかの組成物。
[6] 前記乳酸菌が、ラクトコッカス・ラクティスJCM5805株である、[1]~[3]のいずれかの組成物。
[7] 食品組成物である、[1]~[6]のいずれかの組成物。
[8] 医薬組成物である、[1]~[6]のいずれかの組成物。
[9] 細菌の異常増殖に起因する皮膚の状態が肌荒れ、皮膚炎である、[7]又は[8]の組成物。
[10] 細菌の異常増殖に起因する皮膚の状態がとびひ(伝染性膿痂疹)、蜂窩織炎、丹毒、ブドウ球菌性熱傷様皮膚症候群、毛包炎、にきび、せつ、癰、細菌性爪囲塩、慢性膿皮症及び尋常性毛瘡からなる群から選択される[8]の組成物。
○ とびひ(伝染性膿痂疹)
水泡型 黄色ブドウ球菌
痂皮型 A群β溶血性連鎖球菌
○ 蜂窩織炎
ブドウ球菌、又はA群β溶血性連鎖球菌
○ 丹毒
A群β溶血性連鎖球菌
○ ブドウ球菌性熱傷様皮膚症候群(SSSS:Staphylococcal Scalded Skin Syndrome)
黄色ブドウ球菌
○ 毛包炎(毛嚢炎)
黄色ブドウ球菌及び表皮ブドウ球菌
○ にきび(尋常性ざ瘡)
ニキビは毛包炎の1種であり、青少年の顔面に生じる。
○ せつ(おでき)及び癰(よう)
せつ及び癰(よう)は毛包炎が進行したものをいう。
○ 細菌性爪囲塩
黄色ブドウ球菌、A群β溶血性レンサ球菌及び緑膿菌
○ 多発性汗腺膿瘍(ブドウ球菌性汗孔周囲炎)
黄色ブドウ球菌
○ 慢性膿皮症
黄色ブドウ球菌及び表皮ブドウ球菌
○ 尋常性毛瘡(かみそり負け)
黄色ブドウ球菌及び表皮ブドウ球菌
○ 紅色陰癬
蛍光ジフテロイド
また、アトピー性皮膚炎も黄色ブドウ球菌による感染が症状を悪化させることが報告されており、本発明の組成物はアトピー性皮膚炎の症状の緩和及び改善に用いることもできる。
本発明に使用した黄色ブドウ球菌は以下に示すような方法で調製した。
<実験方法>
Staphylococcus aureus MX2株を米国の生物資源バンクであるAmerican Type Culture Collection(ATCC)より入手した。試験の都度、試験管に普通ブイヨン培地(栄研社製)を10 mL入れ、凍結菌液を融解し、100 μLを接種した後、恒温振盪培養機(タイテック社製)で37℃、振盪培養した。培養後の菌懸濁液を遠心機にて遠心分離(1000 rpm、5分)し、上清を取り除いた。沈殿している菌に生理食塩液2 mLを加え攪拌し、接種菌原液とした。
<結果>
実施例2に使用した黄色ブドウ球菌濃度は3.4 x 106cfu/mL、実施例3に使用した黄色ブドウ球菌濃度は3.0 x 106 cfu/mLであった。
Lactococcus lactis JCM5805を経口摂取させたマウスの皮膚に黄色ブドウ球菌を接種し、病変度評価、黄色ブドウ球菌の生菌数測定、病理組織学的検査、抗細菌性遺伝子発現を実施し、細菌感染に対する防御効果を評価した。
<実験方法>
BALB/Cマウス(日本エスエルシー社より購入。5週齢メス)1群16匹ずつに分け、標準食摂取群(AIN-93G食・オリエンタル酵母工業社製)とLactococcus lactis JCM5805混餌投与群(Lactococcus lactis JCM5805摂取群)の2群を設定した。乳酸菌の投与量は1日1匹あたり1 mgに設定した。乳酸菌の投与開始時を0日として、14日目に塩酸ケタミン麻酔(筋肉内投与,2.0 mL / kg 、塩酸ケタミン注射液;動物用ケタラール(登録商標)50注射液;バイエル薬品株式会社)下でマウスの背部を電気カミソリで剃毛後、除毛クリーム(epilat(登録商標)、クラシエホームプロダクツ株式会社)を剃毛部位に塗り、約2 cm四方の被験部位を設定した。被験部位を布粘着テープで3回ストリッピングした。投与15日目に塩酸ケタミン麻酔下で、再度被験部位を布粘着テープで3回ストリッピングした後、マイクロピペットを用いて被験部位へ黄色ブドウ球菌の接種菌液を個体あたり0.1 mL (3.4×105 cfu/head)滴下した。
<結果>
図1に示すように、Lactococcus lactis JCM5805摂取群は標準食摂取群に比して、黄色ブドウ球菌の皮膚感染に起因する皮膚病変度が有意に低値を示すことが判明した。すなわち、Lactococcus lactis JCM5805には黄色ブドウ球菌皮膚感染による皮膚病変の重症化に対する軽減作用があることが示された。
実施例2で示したLactococcus lactis JCM5805を経口摂取させたマウスの皮膚に黄色ブドウ球菌を接種し、感染に起因する皮膚病変度を経時的に測定することにより、細菌感染に対する防御効果を病変が寛解するまでの期間評価した。
<実験方法>
BALB/Cマウス(日本エスエルシー社より購入。5週齢メス)1群3匹ずつに分け、標準食摂取群(AIN-93G食)とLactococcus lactis JCM5805混餌投与群(Lactococcus lactis JCM5805摂取群)の2群を設定した。乳酸菌の投与量、投与方法、黄色ブドウ球菌の接種は実施例2と同様の方法で行い、黄色ブドウ球菌接種0日目から6日目まで皮膚の病変度を評価した。
<結果>
図4に黄色ブドウ球菌感染後の皮膚病変評点を示した。Lactococcus lactis JCM5805摂取群はコントロール群に比して、すべての時点で病変評点が低値を示すことが判明した。
Lactococcus lactis JCM5805摂取時の皮膚の黄色ブドウ球菌に対する抗菌作用
Lactococcus lactis JCM5805を経口摂取させたマウスの皮膚の抽出液を用い、黄色ブドウ球菌に対する抗菌作用を、標準食を摂取したマウスと比較した。
<実験方法>
BALB/Cマウス(日本チャールズリバー社より購入。7週齢メス)1群8匹ずつに分け、標準食摂取群(AIN-93G食)とLactococcus lactis JCM 5805混餌投与群(Lactococcus lactis JCM5805摂取群)の2群を設定した。乳酸菌の投与量は1日1匹あたり1 mgに設定した。乳酸菌の投与開始時を0日として、14日目に解剖し、背面皮膚を採取した。
<結果>
図5に示すように、Lactococcus lactis JCM5805摂取群は標準食摂取群に比して、Staphylococcus aureus MW2株に対して、菌数が顕著に少なくなっており、抗菌性が高まっていることが示された。
Claims (10)
- 乳酸菌を有効成分として含む、経口摂取により、細菌の異常増殖を抑制し、又は細菌の異常増殖に起因する皮膚状態の悪化を防止又は改善するための組成物。
- 細菌が黄色ブドウ球菌(Staphylococcus aureus)、表皮ブドウ球菌(Staphylococcus epidermidis)、A群β溶血性連鎖球菌(化膿レンサ球菌)(Streptococcus pyogenes)、緑膿菌(Pseudomonas aeruginosa)、蛍光発色性ジフテロイド(蛍光ジフテロイド)及びアクネ桿菌(Propionibacterium acnes)からなる群から選択される請求項1記載の組成物。
- 細菌が黄色ブドウ球菌(Staphylococcus aureus)、表皮ブドウ球菌(Staphylococcus epidermidis)、アクネ桿菌(Propionibacterium acnes)からなる群から選択される、請求項2記載の組成物。
- 前記乳酸菌が、ラクトコッカス属に属するものである、請求項1~3のいずれか1項に記載の組成物。
- 前記乳酸菌が、ラクトコッカス・ラクティスである、請求項1~3のいずれか1項に記載の組成物。
- 前記乳酸菌が、ラクトコッカス・ラクティスJCM5805株である、請求項1~3のいずれか1項に記載の組成物。
- 食品組成物である、請求項1~6のいずれか1項に記載の組成物。
- 医薬組成物である、請求項1~6のいずれか1項に記載の組成物。
- 細菌の異常増殖に起因する皮膚の状態が肌荒れ、皮膚炎である、請求項7又は8に記載の組成物。
- 細菌の異常増殖に起因する皮膚の状態がとびひ(伝染性膿痂疹)、蜂窩織炎、丹毒、ブドウ球菌性熱傷様皮膚症候群、毛包炎、にきび、せつ、癰、細菌性爪囲塩、慢性膿皮症及び尋常性毛瘡からなる群から選択される請求項8記載の組成物。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018539671A JP6652648B2 (ja) | 2016-09-15 | 2017-09-07 | 乳酸菌を有効成分として含む、皮膚における特定細菌の異常増殖に起因する皮膚の状態の悪化を防止又は改善するための組成物 |
CA3036937A CA3036937C (en) | 2016-09-15 | 2017-09-07 | Composition which contains lactic acid bacterium as effective component and which is for preventing or ameliorating skin condition deterioration caused by abnormal proliferation of specific bacterium in skin |
EP17850798.4A EP3513799A4 (en) | 2016-09-15 | 2017-09-07 | COMPOSITION WITH LACTIC ACID BACTERIUM AS AN ACTIVE SUBSTANCE TO PREVENT OR REDUCE SKIN CONDITION THAT IS CAUSED BY THE ABNORMAL PROLIFERATION OF A SPECIFIC BACTERIUM IN THE SKIN |
MYPI2019001274A MY196871A (en) | 2016-09-15 | 2017-09-07 | Composition which contains lactic acid bacterium as effective component and which is for preventing or ameliorating skin condition deterioration caused by abnormal proliferation of specific bacterium in skin |
US16/333,548 US11382939B2 (en) | 2016-09-15 | 2017-09-07 | Composition which contains lactic acid bacterium as effective component and which is for preventing or ameliorating skin condition deterioration caused by abnormal proliferation of specific bacterium in skin |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016-180851 | 2016-09-15 | ||
JP2016180851 | 2016-09-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018051895A1 true WO2018051895A1 (ja) | 2018-03-22 |
Family
ID=61619454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2017/032330 WO2018051895A1 (ja) | 2016-09-15 | 2017-09-07 | 乳酸菌を有効成分として含む、皮膚における特定細菌の異常増殖に起因する皮膚の状態の悪化を防止又は改善するための組成物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US11382939B2 (ja) |
EP (1) | EP3513799A4 (ja) |
JP (1) | JP6652648B2 (ja) |
CA (1) | CA3036937C (ja) |
MY (1) | MY196871A (ja) |
WO (1) | WO2018051895A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019177139A1 (ja) * | 2018-03-15 | 2019-09-19 | キリン株式会社 | 皮膚状態改善用組成物 |
JP2020079236A (ja) * | 2018-11-12 | 2020-05-28 | 有限会社バイオ研 | 皮膚塗布用の皮膚創傷治癒促進組成物、その製造方法、及び創傷被覆材 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002171933A (ja) * | 2000-12-07 | 2002-06-18 | Ko Gijutsu Kenkyusho:Kk | キムチエキス健康食品 |
JP2003259860A (ja) * | 2002-03-06 | 2003-09-16 | Meishun Tei | ラクトコッカス・ラクチスcbt−19及びこれを利用した抗菌培養液の分離濃縮物の製造方法並びにこれを包含する化粧料組成物 |
JP2007537224A (ja) * | 2004-05-14 | 2007-12-20 | グリコロジック リミテッド | 改良されたプレバイオティック |
US20080233091A1 (en) * | 2003-10-17 | 2008-09-25 | Paul Ross | Use of Probiotic Bacteria in the Treatment of Infection |
US20090214497A1 (en) * | 2005-01-29 | 2009-08-27 | Problonic Inc. | Novel Acid Tolerant Lactobacillus Sakei Probio-65 with the Ability of Growth Suppression of Pathogenic Microorganisms and the Anti-Allergic Effect |
JP2014513106A (ja) * | 2011-05-06 | 2014-05-29 | オルガノバランス メディカル アーゲー | 新規な乳酸菌及びそれを含有する組成物 |
JP2016508712A (ja) * | 2012-12-17 | 2016-03-24 | ラボラトワール ユルゴ | 黄色ブドウ球菌、緑膿菌、化膿性連鎖球菌、エンテロコッカス・フェシウム、エンテロバクター・クロアカ、プロテウス・ミラビリス、バクテロイデス・フラジリス、表皮ブドウ球菌、アクネ菌、カンジダ・アルビカンス、および/または癜風菌に関連する感染、コロニー形成、または病気を予防および/または治療する方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1736537A1 (en) | 2005-06-22 | 2006-12-27 | OrganoBalance GmbH | Methods and means for protecting the skin against pathogenic microorganisms |
FR2938437B1 (fr) | 2008-11-19 | 2020-03-27 | Société des Produits Nestlé S.A. | Utilisation cosmetique de microorganisme pour le traitement des peaux grasses |
RU2562097C2 (ru) * | 2009-05-13 | 2015-09-10 | Конинклейке Филипс Электроникс Н.В. | Резкий переход в круговом световодном кольце для пользовательского интерфейса с функциональными возможностями с определенным началом и концом |
KR101918792B1 (ko) | 2011-05-16 | 2018-11-14 | 오르가노발란스 메디컬 아게 | 박테리아성 감기에 대한 신규 락트산 박테리아 및 그를 함유하는 조성물 |
GB201206599D0 (en) | 2012-04-13 | 2012-05-30 | Univ Manchester | Probiotic bacteria |
WO2015182735A1 (ja) * | 2014-05-30 | 2015-12-03 | キリン株式会社 | 乳酸菌免疫賦活作用増強組成物及び乳酸菌免疫賦活作用増強方法 |
KR101618330B1 (ko) * | 2015-03-27 | 2016-05-09 | 중앙대학교 산학협력단 | 락토코커스 중앙젠시스를 유효성분으로 함유하는 염증성 질환의 예방 또는 치료용 약학적 조성물 |
ITUB20153106A1 (it) | 2015-08-13 | 2017-02-13 | Probiotical Spa | Composizione di batteri lattici per uso nel trattamento delle infezioni causate da Propionibacterium acnes e in particolare per l'acne |
JP6846376B2 (ja) * | 2018-03-15 | 2021-03-24 | キリンホールディングス株式会社 | 皮膚状態改善用組成物 |
-
2017
- 2017-09-07 EP EP17850798.4A patent/EP3513799A4/en active Pending
- 2017-09-07 CA CA3036937A patent/CA3036937C/en active Active
- 2017-09-07 JP JP2018539671A patent/JP6652648B2/ja active Active
- 2017-09-07 US US16/333,548 patent/US11382939B2/en active Active
- 2017-09-07 MY MYPI2019001274A patent/MY196871A/en unknown
- 2017-09-07 WO PCT/JP2017/032330 patent/WO2018051895A1/ja unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002171933A (ja) * | 2000-12-07 | 2002-06-18 | Ko Gijutsu Kenkyusho:Kk | キムチエキス健康食品 |
JP2003259860A (ja) * | 2002-03-06 | 2003-09-16 | Meishun Tei | ラクトコッカス・ラクチスcbt−19及びこれを利用した抗菌培養液の分離濃縮物の製造方法並びにこれを包含する化粧料組成物 |
US20080233091A1 (en) * | 2003-10-17 | 2008-09-25 | Paul Ross | Use of Probiotic Bacteria in the Treatment of Infection |
JP2007537224A (ja) * | 2004-05-14 | 2007-12-20 | グリコロジック リミテッド | 改良されたプレバイオティック |
US20090214497A1 (en) * | 2005-01-29 | 2009-08-27 | Problonic Inc. | Novel Acid Tolerant Lactobacillus Sakei Probio-65 with the Ability of Growth Suppression of Pathogenic Microorganisms and the Anti-Allergic Effect |
JP2014513106A (ja) * | 2011-05-06 | 2014-05-29 | オルガノバランス メディカル アーゲー | 新規な乳酸菌及びそれを含有する組成物 |
JP2016508712A (ja) * | 2012-12-17 | 2016-03-24 | ラボラトワール ユルゴ | 黄色ブドウ球菌、緑膿菌、化膿性連鎖球菌、エンテロコッカス・フェシウム、エンテロバクター・クロアカ、プロテウス・ミラビリス、バクテロイデス・フラジリス、表皮ブドウ球菌、アクネ菌、カンジダ・アルビカンス、および/または癜風菌に関連する感染、コロニー形成、または病気を予防および/または治療する方法 |
Non-Patent Citations (1)
Title |
---|
CHARLIER, CATHY ET AL.: "Acidification is not involved in the early inhibition of Staphylococcus aureus growth by Lactococcus lactis in milk", INT. DAIRY J., vol. 18, 2008, pages 197 - 203, XP022368393, DOI: doi:10.1016/j.idairyj.2007.03.015 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019177139A1 (ja) * | 2018-03-15 | 2019-09-19 | キリン株式会社 | 皮膚状態改善用組成物 |
US11497778B2 (en) | 2018-03-15 | 2022-11-15 | Kirin Holdings Kabushiki Kaisha | Composition for improving skin conditions |
JP2020079236A (ja) * | 2018-11-12 | 2020-05-28 | 有限会社バイオ研 | 皮膚塗布用の皮膚創傷治癒促進組成物、その製造方法、及び創傷被覆材 |
JP7045671B2 (ja) | 2018-11-12 | 2022-04-01 | 有限会社バイオ研 | 皮膚塗布用の皮膚創傷治癒促進組成物、その製造方法、及び創傷被覆材 |
Also Published As
Publication number | Publication date |
---|---|
EP3513799A1 (en) | 2019-07-24 |
CA3036937C (en) | 2023-01-17 |
EP3513799A4 (en) | 2020-04-29 |
US20200179463A1 (en) | 2020-06-11 |
JP6652648B2 (ja) | 2020-02-26 |
CA3036937A1 (en) | 2018-03-22 |
US11382939B2 (en) | 2022-07-12 |
JPWO2018051895A1 (ja) | 2019-06-24 |
MY196871A (en) | 2023-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102970997B (zh) | 抗肥胖剂、抗肥胖用饮食品、糖耐量改善剂和糖耐量改善用饮食品 | |
Mohammad et al. | Probiotic properties of bacteria isolated from bee bread of stingless bee Heterotrigona itama | |
TWI463986B (zh) | 胚芽乳酸桿菌cmu995菌株之新用途 | |
Mojibi et al. | Cell-bound exopolysaccharide extract from indigenous probiotic bacteria induce apoptosis in HT–29 cell-line | |
CN113755409B (zh) | 一种缓解胰岛素抵抗的长双歧杆菌及其应用 | |
TWI337079B (en) | Compositions comprising oligosaccharides | |
RU2667122C2 (ru) | Применение тиосульфата для усиления антипатогенного действия лактобацилл | |
JP6574815B2 (ja) | 脂肪分解能を有する菌株を含む脱毛症防止または発毛促進用の組成物 | |
Oyewole et al. | In vitro Study of Potential Probiotic Lactic Acid Bacteria Isolated from The Gut of Chickens in Abeokuta, Nigeria. | |
KR20130048946A (ko) | 락토바실러스 루테리 cs132 또는 이의 배양물을 포함하는 항암용 조성물 | |
WO2018051895A1 (ja) | 乳酸菌を有効成分として含む、皮膚における特定細菌の異常増殖に起因する皮膚の状態の悪化を防止又は改善するための組成物 | |
JP2013116089A (ja) | 抗ヘリコバクター・ピロリ効果を有する乳酸菌株、その乳酸菌株を含む抗ヘリコバクター・ピロリ剤、及びその乳酸菌株を含む飲食品 | |
KR100954882B1 (ko) | 조류 인플루엔자 바이러스 감염억제 효과를 가지는 신규 유산균 및 이를 포함하는 조성물 | |
TWI829090B (zh) | 抗憂鬱劑、抗老化劑及抗肥胖劑 | |
JP2012180288A (ja) | 抗菌剤 | |
KR20190102498A (ko) | 질염 원인균에 대한 증식억제활성을 갖는 락토바실러스 속 균주 조합 및 이를 유효성분으로 함유하는 제품 | |
KR20120010040A (ko) | 바실러스 세레우스에 항균력을 갖는 식물유래 천연항균 조성물 | |
KR102290381B1 (ko) | 락토바실러스 플란타룸 v135 균주 또는 상기 균주의 사균체를 유효성분으로 함유하는 알코올성 간염의 예방, 개선 또는 치료용 조성물 | |
TWI734333B (zh) | 減少體脂肪之益生菌株及其組合物與用途 | |
RU2806746C2 (ru) | Композиция для предупреждения, лечения или облегчения желудочно-кишечных заболеваний, содержащая штамм рода Corynebacterium и продукт его культивирования | |
KR102384755B1 (ko) | 신규한 락토코커스 중앙젠시스 cau 1447 균주 | |
US20240165173A1 (en) | Method of reducing uric acid by using lactobacillus paracasei lt12 | |
Na et al. | Antibacterial and Antifungal Activity of Lactobacillus Plantarum Isolated from Green Tea | |
TWI458438B (zh) | Fermentation and culture methods, plant fermentation extracts, plant fermentation extract powders, and plant fermentation extract complexes | |
Albookarami | Investigating the role of probiotics in coping with cancer and health in society |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17850798 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2018539671 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3036937 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2017850798 Country of ref document: EP Effective date: 20190415 |